Elderly asthmatics are at a higher risk for morbidity and mortality from their asthma than younger patients. There are important age-related physiologic and immunologic changes that complicate the presentation, diagnosis, and management of asthma in the aged population. Evidence suggests that elderly asthmatics are more likely to be underdiagnosed and undertreated. Additionally, elderly patients with asthma have highest rates of morbidity and mortality from their disease than younger patients.
decreased, this is not true of the elderly.
3, 14, 15 Of aged patients, those who are female, Black, Hispanic, and from a lower-income group are at the greatest risk for frequent hospitalizations. 2 The reasons for these trends are multifactorial and include underdiagnosis of asthma, 16 the presence of other comorbid conditions, underperception of asthma symptoms, [17] [18] [19] potential cognitive decline with aging, and adverse effects from polypharmacy. Inhaled corticosteroids (ICSs), the cornerstone of chronic asthma management, are also underutilized in elderly patients. 9, 20, 21 Although ICS use reduces hospital admissions and mortality in this population, 22 they may be less effective in older patients with asthma, who are more likely to have predominantly neutrophilic inflammation. [23] [24] [25] [26] Clearly, a better understanding of the underlying pathophysiology in this population warrants further study.
| AGING AND LUN G STRUCTURE
There are several age-related changes in lung physiology and morphology that occur and likely impact asthma. Aging is associated with a marked decrease in elastic recoil, greater chest wall rigidity, and reduced respiratory muscle strength. Estenne et al 27 demonstrated a 31% reduction in chest wall compliance with aging among 52 subjects aged 24-75 years. The reduced chest wall compliance is a result of calcification of costochondral junctions, costal cartilage, and degenerative joint disease of the spine as well as partial and complete osteoporotic fractures increasing dorsal kyphosis. 28 Maximum inspiratory and expiratory pressures are reduced secondary to diaphragmatic weakness and correlate to age-related skeletal muscle weakness. 28, 29 Respiratory muscle weakness is frequently magnified in patients with comorbidities (neurologic, cardiac, renal disease), frailty and poor nutrition, all more prevalent among the elderly. 30, 31 It has been long recognized that there are also important age-related changes in the lung parenchyma. In a postmortem study, there was significant age-related peripheral airway narrowing with reduced airway surface-to-volume ratio. 32 The term "senile lung" has been coined and Verbeken et al 33 in 1992 reported alveolar dilation and ductal ectasia without emphysematous destruction or fibrosis from lungs of elderly patients without previously known lung disease.
Decreased elastic recoil, detected in the aging lung, is felt to be a result of these morphologic changes. The sum result of the age-associated changes, including reduced chest wall compliance, decreased respiratory muscle strength, and the macro-and microscopic changes in the lung parenchyma, is postulated to have a significant role in altering pulmonary function. In particular, older patients, even without lung disease, are more likely to have obstructive and mixed patterns with increased residual volume (RV), and reductions in forced expiratory volume in 1 second (FEV 1 ), FEV 1 /FVC ratio, and FVC with a minimal change in total lung capacity. 28 The decline in FEV 1 generally begins to occur between 25 and 30 years of age and is initially linear (approximately 28 mL/year in men and 25 mL/year in females)
but accelerates with increasing age. 34 The age-related decline in FEV 1 is further accelerated in patients with asthma (when controlling for smoke exposure) compared to those without lung disease. 35 Therefore, it is critical to use age-adjusted values when interpreting spirometry results in older patients to avoid overdiagnosis of respiratory impairment. 36 
| CE LLULAR BIOLOGY OF THE AGIN G LUNG
The physiologic and histopathologic findings in the airways of aging subjects are driven by important cellular age-associated changes.
Acknowledging the importance of aging and lung disease, the American Thoracic Society (ATS) highlighted this topic at the 2014 annual meeting. 37 The summary statement recommended to address several of the following "tentative hallmarks" of mammalian aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication 38 when studying lung disease in older patients. At present, most work investigating these cellular hallmarks of aging in the lung has focused on COPD and pulmonary fibrosis. However, a reduced telomere length in peripheral blood mononuclear cells (PMNs) correlated with increased asthma severity in a small group of patients (aged 25-60 years) 39 and in another study, was more likely detected in patients with childhood-onset persistent vs adolescentonset asthma. 40 Additionally, in a murine model of asthma, inhibiting thymic stromal lymphopoietin (TSLP) decreased cellular senscence. 41 Additional future work is needed to more fully address the impact of cellular senescence with asthma.
The immune system is complex and is divided into the innate and the adaptive responses. The innate arm provides an initial defense against pathogens through noncellular (eg, C-reactive protein, man- The number of neutrophils in the airway of aging individuals without airway disease increases. 57, 58 This impact on asthma is not clear. Emerging data suggest that older patients with asthma have increased sputum neutrophils compared with younger patients, [23] [24] [25] even when controlling for aging, 26 with increased levels of neutrophil mediators including MMP-9, neutrophil elastase, and interleukin (IL)-8, resembling changes seen in a phenotype of severe asthma noted in some younger adults. Determining underlying airway inflammation in older adults with asthma is important as neutrophilic asthma is often less responsive to corticosteroid treatment, 59 suggesting that alternative therapies may be indicated for older patients.
There is a limited understanding of the age-associated changes in eosinophil number and function in older patients with asthma. Eosi- responsiveness. 62 However, the development of BHR later in life was associated with elevated peripheral blood eosinophil counts in males (mean age 60 years) enrolled in the Normative Aging Study. 63 Thus, eosinophils may be less functional in the elderly and their role in BHR is not presently well established.
The ability to mount an adaptive immune response declines with increasing age. There is a reduced ability of B cells to produce specific and long-lasting antibodies to antigens (eg, vaccination, infection) and a lack of a rapid immunologic response when encountering pathogens. 64 Aging decreases T-cell receptor (TCR) signaling and diversity, which results in a loss of T-cell proliferation and decreased viral clearance. [65] [66] [67] With age, the thymus gland, the producer of mature T cells, begins to involute, and by 75 years of age is almost completely replaced with fatty tissue. 68 Although the number of na€ ıve T cells decreases with aging, the total number of circulating T cells remain relatively constant due to an increased resistance to apoptosis of memory T cells. 69 Additionally, there is an age-related decline in CD8+ T cells and an increase in CD4/CD8 ratio. cell frequency appears to increase with aging. 77 Recent data in aged mouse models of asthma also demonstrate an increased expression of airway Th17 expression. 78 It will be important to ascertain whether Th17 increases further with aging and asthma. Increased IL-17 in older patients with asthma likely contributes to increased airway neutrophilia and may be an additional target for therapy of asthma in this group of patients with difficult-to-treat disease.
In the general population, including individuals with and without atopy, total IgE declines with increasing age, typically peaking around age 20 years. [79] [80] [81] However, some studies have not reported this trend. [82] [83] [84] Allergen-specific IgE also decreases with aging. Studies including healthy subjects with and without asthma and other atopic diseases suggest that approximately 40%-50% of subjects under the age of 50 years and approximately 35% of subjects older than 50
are IgE sensitized to at least one allergen. 81, [83] [84] [85] However, whether
IgE antigen sensitization and subsequent exposure alter asthma severity is not well established in the aged patient with asthma.
In summary, the changes in the aging immune system are complex and not fully understood in aging asthmatics and require further study.
While there is evidence of increased neutrophilic inflammation and Th17-mediated pathology in elderly patients with asthma, the eosinophil and Th2-mediated inflammation likely play an important role as well.
| AIRWAY REMODELING AND AGING
Airway remodeling, structural changes in the airways and lung parenchyma, can occur in asthma and is felt in part to be secondary to persistent inflammation. The features of airway remodeling include subepithelial fibrosis, goblet, and submucosal gland hyperplasia, increased airway smooth muscle mass, and increased airway vascularity and occur in both the large and small airways and in patients with all disease severities. 86 The duration of asthma likely impacts airway remodeling; therefore, it is hypothesized that older patients with LSA have increased features of airway remodeling; however, this has not been definitively established.
Subepithelial fibrosis is marked by increased deposition and decreased degradation of the extracellular matrix. There is an increase in extracellular collagens I, III, and V. Progenitor cells and myofibroblasts are felt to be the primary effector cell involved in this process. Increased TGF-b and decreased activity of matrix metalloproteinases have also been implicated. 87 Airway smooth muscle cell mass has long been recognized to be increased in severe asthmatics due to cellular hyperplasia and hypertrophy. This increase in cell division (hyperplasia) is mediated by mitogens which lead to activation of tyrosine kinases and G-protein-coupled receptors and in turn, intracellular stimulation of mitogen-activated protein kinases. These pathways are upregulated by normal mitogens and potentially inflammatory cytokines seen in the airways of asthmatics. 88 Alternatively, there is also some evidence that peripheral recruitment of circulating progenitor myofibroblasts may also be a mechanism of increased airway smooth muscle cell mass seen in asthmatics. 89 It is implied that airway remodeling is likely more important in long-standing elderly asthmatics who have these changes superimposed upon normal aging lung rather than LOA, or in younger patients with asthma; however, this requires further study. In 6-month vs 6-week-old antigen-sensitized and airway-challenged mice, there was increased staining for mucus, peribronchial collagen, and smooth muscle staining in the aged group. 90 Histologic evaluation of younger (ages however, unlike in younger patients, they are not well characterized.
Older patients with asthma are loosely classified based upon their age of asthma onset and duration of disease into (i) long-standing asthma (LSA), (ii) late-onset asthma (LOA), or (iii) remitting childhood asthma that recurs at a later age. The age cutoff for the diagnosis of LOA is not consistent: >12 years of age in some studies and up to >65 years in others. 93 As many as 40% of patients >60 years of age with current asthma report their first symptom onset after the age of 40 years. 10, 94 LSA typically develops before the age of 12 years.
Atopy appears to have a minimal role on the development of LOA compared with LSA. Factors predicting LOA include smoking, new habitual snoring, new rhinitis symptoms, chronic sinus symptoms, weight gain, and obesity (especially among females). [95] [96] [97] [98] Observational studies report that nearly 50% of subjects with asthma onset after the age of 60 years had a respiratory tract infection just prior to the onset of their symptoms. 43 Although viral infections are common triggers for asthma inception, Chlamydia pneumonaie and other atypical infections may be the etiology in some patients with LOA. 99 Exposure to dust particles, art supplies, and cleaning products have been reported to induce LOA in some patients.
100,101
Whether asthma is early or late onset and its duration likely have prognostic implications. Patients with LOA tend to have a higher baseline FEV 1 , and a more pronounced bronchodilator response than those with LSA, who are more likely to have irreversible or partially reversible airway obstruction, and greater airway hyperinflation. 102, 103 For patients enrolled in the Severe Asthma Research Program (SARP), both aging and duration of disease were important risk factors for severity, although the absolute age had a greater effect than disease duration. 104 Park et al 105 evaluated 872 patients with asthma >65 years of age using cluster analysis and reported that those with the longest duration of disease had higher risks for acute exacerbations and accelerated lung function decline than those with a more recent asthma onset and a more normal lung function.
| DIAGNOSIS OF ASTHMA IN OLDE R ADULTS
Similar to younger patients, the diagnosis of asthma in the aged requires the presence of compatible symptoms (eg, chest tightness, intermittent and nocturnal wheezing, and dyspnea). In some patients, cough may be the only symptom. 106 Older, compared to younger patients with asthma, may be poor perceivers of dyspnea even in the presence of significant airflow obstruction. 107, 108 Dyspnea is also a common symptom of other chronic disorders (heart failure, anemia, etc.); therefore, asthma as an etiology may be overlooked. Additionally, some older patients may limit their activity to avoid becoming dyspneic, or attribute it to aging itself, therefore, making following asthma control or diagnosis of LOA more difficult. Therefore, in order to avoid misdiagnosis, it is important to rule out other common chronic respiratory problems such as COPD and as well as more rare causes of chronic airflow obstruction including bronchiectasis and constrictive bronchiolitis in aged patients.
The same objective measures used to diagnose asthma in younger patients are performed in older patients; however, there are Finally, bronchoprovocation challenges may be contraindicated in some elderly patients due to low baseline lung function or cardiac comorbidities.
| MANAGEMENT OF ASTH MA IN THE ELDE RLY
The management of asthma in elderly patients is directed at controlling symptoms and eliminating or reducing exacerbating triggers.
Specifically relating to older patients, there are important exacerbating factors including comorbid diseases, appropriate medication usage, drug-drug interactions and drug side-effects, and physiologic differences, that all must be considered to achieve these goals (see Table 2 ).
| ENVIRONMENTAL AND PH ARMACOLOGIC EXPOSURES
While atopy in older patients with asthma is not as prevalent as it is in younger patients, it is not uncommon. Studies from the United States, the Netherlands, and France report specific antigen IgE sensitization rates in older adults with asthma between 23.9% and 74%. [124] [125] [126] [127] The most common aeroallergens to which older patients are sensitized are not consistent among studies, but typically include cats, 124 dust mites, 125, 128 and cockroaches. 129 Whether atopy worsens asthma outcomes in aged patients is not known. Some studies including older subjects with asthma suggest that an atopic history may increase disease severity. 
| Rescue medications
Although all patients with asthma require a rescue medication, there are several potential considerations that must be addressed. Beta 2 -receptor density, responsiveness, and affinity may decline with age;
however, this has not been consistently established. 141, 142 This outcome could reduce the response to this group of acute bronchodilators among elderly patients. Older patients may be more sensitive to adverse effects of beta 2 -agonists, particularly those with unstable cardiovascular disorders. 143, 144 Animal models suggest that parasympathetic activity decreases with aging, but relatively little is known about the effect of aging on anticholinergic responses in humans.
Short-acting anticholinergic medications may be useful bronchodilators in the elderly and do not have the cardiac side-effects of beta 2 -agonists. Although more likely with oral anticholinergics, cognitive impairment, falls, symptomatic urinary outlet obstruction, and closedangle glaucoma are potential risks with inhaled preparations; therefore, careful monitoring of older patients prescribed these medications should occur. 145 
| Controller therapies
ICSs are an important backbone of controller therapy in patients with persistent asthma. ICSs are most efficacious in patients with eosinophilic, Th2-mediated asthma. Th-17-mediated asthma, marked by neutrophilic inflammation, has been recognized to be less responsive to ICS therapy and is likely more common among older asthmatics. 26 A large, retrospective review of 10 landmark asthma trials in patients with mild-moderate disease on ICS therapy found an agerelated increase in treatment failures. 146 In this analysis, the number of patients receiving inhaled corticosteroids was significantly higher than all other therapies, suggesting that it may have been underpowered to detect a similarly increased risk with other controller medications. Despite these data, ICS therapy is still currently the preferred medication for older patients with persistent disease. Furthermore, as older asthmatics have been reported to have more small airway involvement, 92 using ultrafine particle ICS medications may be beneficial. To the best of our knowledge, this has not been studied in this age group. Older patients receiving higher-dose ICS should be monitored closely for decreased bone mineral density, increased fracture risk, and cataracts. 147, 148 The safety of long-acting beta-ago- The most recent advances in asthma therapy have led to the development of targeted biologic therapy directed at interleukins known to drive specific subtypes of asthma. Anti-IL-5 therapy with mepolizumab, reslizumab, and benralizumab has been shown, in phase III trials to be efficacious in reducing asthma attacks and improving lung function in poorly controlled asthmatics. Anti-IL-4R-alpha (dupilumab), anti-IL-13 (tralokinumab), and other targeted therapies hold promise as potential future targeted therapies in asthma.
These therapies have been well recognized to be efficacious, in carefully selected subsets of asthmatics with eosinophilic airway inflammation. Subgroup analysis from recent trial data has suggested that mepolizumab is effective in elderly asthmatics with eosinophilic inflammation. 158 Given their cost, their use will likely be reserved for the severe asthmatics patients who are not controlled on conventional therapy. In clinical practice, many elderly asthmatics will likely fall into this category; however, the proportion of elderly patients with eosinophilic airway inflammation will likely be less than younger age groups. The use of these agents in elderly asthmatics will need to be reserved for carefully selected patients.
In summary, there is a paucity of prospective data to determine the best management approaches for this important group of asthmatics. Given the recognition of the heterogeneity of asthma, there 
| FUTURE DIRECTIONS FOR RESEARCH
Given the recent recognition of the heterogeneity of asthma and the growing appreciation of the morbidity and mortality among elderly asthmatics, there is a great need for further basic, translation, and clinical research targeting older patients. The recognition of the multiple mechanisms of biologic aging relevant to the asthmatic lung, including, but not limited to, telomere length, mitochondrial dysfunction, autophagy, DNA methylation, immunosenescence, and airway remodeling, is an area for research into mechanisms and potential new therapeutics in asthma. Given the newer targeted therapies on the horizon, it will also be important to determine their role in the management of elderly patients with long-standing asthma and those with late-onset asthma.
| CONCLUSION
The underlying pathophysiology and optimal management of asthma among older patients has long been overlooked. This is despite older patients with asthma having the highest morbidity and mortality rates from their disease, as shown in Figure 1 . Asthma pathophysiology in older patients is complex in that it is imposed on physiologic changes of the airway associated with aging and changes of inflammation with aging. Consequently, asthma in older patients is less likely to respond to traditional asthma therapies including inhaled corticosteroids. As new asthma pharmacologic therapies are developed and treatment becomes more personalized to individual phenotypes of asthma, it will be vital to include elderly asthmatics (with late-onset and long-standing disease) into large clinical trials to further tailor therapy Figure 1 .
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